# Coenzyme Q10 Deficiency in ME/CFS and Statin Contraindication

**Authors:** Michael Maes, Ivanka Mihaylova, Marta Kubera, Marc Uytterhoeven, Nicolas Vrydags, Eugene Bosmans
**Journal:** Neuro Endocrinology Letters, 2009, 30(4):470-476
**DOI:** Not available in PubMed record
**PMID:** 20010505
**URL:** https://pubmed.ncbi.nlm.nih.gov/20010505/

## Key Points

1. **CoQ10 deficiency is common in ME/CFS**: 44.8% of patients had values below the lowest control value (490 μg/L)

2. **Inverse correlation with symptoms**: Lower CoQ10 associated with:
   - More severe fatigue
   - Worse autonomic symptoms
   - Greater neurocognitive deficits (especially concentration problems)

3. **Severely depleted patients**: Those with CoQ10 < 390 μg/L showed significantly worse neurocognitive deficits (p<0.01)

4. **Cardiovascular mortality risk**: CoQ10 deficiency may explain increased cardiovascular mortality in ME/CFS (approximately 25 years earlier than general population)

5. **CRITICAL CLINICAL IMPLICATION**: **Statins significantly decrease plasma CoQ10, therefore ME/CFS should be regarded as a relative contraindication for statin treatment without CoQ10 supplementation**

## Methodology

- **Study Design:** Case-control study
- **Sample Size:** 58 ME/CFS patients, 22 normal controls
- **Measurement:** Plasma CoQ10 levels
- **Statistical Analysis:** Comparison between groups, correlation with symptom severity

## Clinical Implications

This paper establishes a clear mechanistic concern about statin use in ME/CFS:

1. **ME/CFS patients already have low CoQ10** (baseline deficiency)
2. **Statins further deplete CoQ10** (HMG-CoA reductase inhibition affects mevalonate pathway)
3. **Double jeopardy**: Using statins in ME/CFS patients could worsen an existing deficiency
4. **Potential consequences**: Exacerbation of fatigue, autonomic dysfunction, cognitive symptoms, and cardiovascular risk

## Relevance to Statin Controversy

This paper provides mechanistic support for the **"statins as harmful"** perspective in ME/CFS, rather than therapeutic. The key argument:

- ME/CFS is a CoQ10-deficient state
- Statins worsen CoQ10 deficiency
- Therefore, statins are contraindicated unless supplementation is provided

## Certainty Assessment

- **Study Quality:** Medium
- **Sample Size:** Modest (n=58 ME/CFS, n=22 controls)
- **Replication:** Multiple studies have confirmed CoQ10 deficiency in ME/CFS
- **Conflicts of Interest:** Not stated in abstract
- **Limitations:**
  - No intervention trial testing statin effects directly
  - Observational design
  - Single-center study
  - CoQ10 deficiency mechanism in ME/CFS not fully established

## Integration Notes

**Certainty Level for Integration:** Medium to High for the CoQ10 deficiency finding; Medium for statin contraindication recommendation (logical inference from mechanism, not direct clinical trial)

**Key Citations:**
- Michael Maes is a prominent ME/CFS researcher with extensive publications on oxidative stress and inflammation
- This paper is frequently cited in discussions of mitochondrial dysfunction in ME/CFS
